Day: March 23, 2022

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and $31.25M private placement PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the year ended December 31, 2021, and highlighted recent corporate accomplishments. “Context has bolstered our corporate, financial, and scientific efforts over the past two quarters. We’ve grown our R&D and operations teams, reported positive data on lead product candidate onapristone extended release (“ONA-XR”) in early breast cancer, and closed on...

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

– Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination – Initiating trials combining EOS-448 and Jemperli in triplet regimens with inupadenant and GSK’s investigational anti-CD96 antibody, GSK6097608 – Advanced clinical development of inupadenant, EOS-850, an A2Areceptor antagonist, start of expansion studies in PD-1 resistant melanoma in combination with pembrolizumab as well as a study further exploring novel predictive biomarkers – Cash balance of $848.5MM as of December 31, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupadenant and growing pipeline of preclinical...

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds Dosed first patient in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold conference call on March 23, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 23, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2021. Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer,...

Acceleware Announces Second Non-Brokered Private Placement of 10% Unsecured Convertible Debentures

Written by Customer Service on March 23, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware”) (TSXV: AXE), a Canadian clean-tech innovator of radio frequency (RF) heating technologies today announced that, due to strong investor demand, it is launching a second non-brokered private placement of 10% unsecured convertible debentures due 2026 (the “Second Debentures”), for approximate gross proceeds of $1,000,000 (the “Second Private Placement”). For details about the first private placement, please see the press release of Acceleware dated March 1, 2022. Details of the Second Private Placement Each Second Debenture matures four years after the issue date and is convertible into units of Acceleware at a conversion price of $0.80. If Acceleware subsequently sells common...

Digital Gaming Experiences at Scale Run on Sumo Logic

Written by Customer Service on March 23, 2022. Posted in Public Companies.

Sumo Logic Announces Support for AWS for Games SAN FRANCISCO, March 23, 2022 (GLOBE NEWSWIRE) — Game Developer Conference – Sumo Logic (Nasdaq: SUMO), the SaaS analytics platform to enable reliable and secure cloud-native applications, announced support for the AWS for Games initiative from Amazon Web Services (AWS) to accelerate digital gaming experiences at scale. Major gaming brands, including Games 24 x 7 and others, already use Sumo Logic to build, run and secure gaming and entertainment applications. With Sumo Logic, game developers can ensure great player experiences, safeguard sensitive data, and accelerate game releases. “The digital transformation that accelerated as the world dealt with the pandemic pushed the cloud to the forefront as the world’s primary gaming ecosystem,” said Christian Beegden, Co-Founder and CTO,...

Nokia Corporation: Repurchase of own shares on 23.03.2022

Written by Customer Service on March 23, 2022. Posted in Public Companies.

Nokia CorporationStock Exchange Release23 March 2022 at 21:00 EET Nokia Corporation: Repurchase of own shares on 23.03.2022 Espoo, Finland – On 23 March 2022 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 233,608 4.89CEUX 16,858 4.89AQEU 16,339 4.89TQEX 9,695 4.90Total 276,500 4.89* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the current authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in traches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation...

Comstock Acquires the Ansel at Rockville Town Center

Written by Customer Service on March 23, 2022. Posted in Public Companies.

Company’s 2nd Acquisition at Rockville Metro Positions BLVD as Premier Luxury Residential Offering RESTON, Va., March 23, 2022 (GLOBE NEWSWIRE) — Comstock Holding Companies, Inc. (Nasdaq: CHCI) (“Comstock”) announced today that it has completed the acquisition of Ansel on behalf of a joint venture between CHCI and Comstock Partners, LC, an affiliated, privately-held company. The 250-unit, 18-story, luxury high-rise apartment building is located at 33 Monroe Street in Rockville at the entrance to Metro’s Rockville Station in the heart of the I-270 Technology and Life Science Corridor in Montgomery County. Comstock acquired the project upon substantial completion and will begin leasing, managing, and rebranding the property as BLVD Ansel. The mixed-use property is the sister building to Comstock’s recently acquired BLVD Forty Four,...

Identity & Access Management (IAM) Solutions Provider BIO-key to Participate in Maxim Group Emerging Growth Conference, March 28-30th

Written by Customer Service on March 23, 2022. Posted in Public Companies.

WALL, N.J., March 23, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), today announced that its Chairman and CEO Mike DePasquale will participate in the Maxim Group Emerging Growth Virtual Conference, March 28-30, 2022. The conference will feature company presentations, fireside chats, and roundtable discussions moderated by Maxim Research Analysts – accessible from the conference registration page starting on March 28th. Investors who would like to schedule a call or meeting with BIO-key’s CEO should contact BIO-key’s IR team via their contact information below. About Maxim Group LLC (www.maximgrp.com)Maxim Group LLC is a full-service investment banking, securities and wealth...

Lam Research President and CEO Tim Archer Testifies Before the United States Senate Commerce Committee

Written by Customer Service on March 23, 2022. Posted in Public Companies.

WASHINGTON, March 23, 2022 (GLOBE NEWSWIRE) — Lam Research Corp. (NASDAQ: LRCX) President and CEO Tim Archer testified today before the United States Senate Committee on Commerce, Science, and Transportation for a hearing entitled, “Developing Next Generation Technology for Innovation.” The hearing examined a variety of topics including the correlation between American competitiveness and semiconductors, the impact of vulnerabilities in semiconductor supply chains and the importance of CHIPS legislation within the U.S. Innovation and Competition Act (USICA) of 2021 and the America COMPETES Act of 2022. “Today’s hearing was another step forward in both tackling the challenges and embracing the opportunities facing the United States semiconductor industry,” said Tim Archer, president and CEO of Lam Research. “I would like to thank...

Beroni Group to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT

Written by Customer Service on March 23, 2022. Posted in Public Companies.

NEW YORK and SYDNEY, Australia, March 23, 2022 (GLOBE NEWSWIRE) — Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced today that the Company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT. Sign up here to access the presentation During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITs, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure,...

Day: March 23, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice